ASCO 2020: aanbevolen abstracten voor longkanker

Raadpleeg ook literatuurlijst niet-toxische middelen en behandelingen specifiek bij longkanker van arts-bioloog drs. engelbert Valstar.

29 mei 2020: Bron: ASCO 2020

Hieronder aanbevolen abstracten door Dr. Sarah Goldberg gepubliceerd op ASCO 2020 gerelateerd aan longkanker.

Klik op de vet gemaakte abstractnummers voor de abstracten:

Plenary Session: Lung Cancer

LBA5 Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. RS Herbst, M Tsuboi, T John, et al

Session: Lung Cancer—Non-Small Cell Metastatic

9500 Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. SS Ramalingam, TE Ciuleanu, A Pluzanski, et al

Take-Home Message

In this study, patients with stage IV recurrent non–small cell lung cancer (NSCLC) and PD-L1 expression of 1% or higher were randomized to receive nivolumab with ipilimumab, nivolumab alone, or chemotherapy. OS at 3 years was 33%, 29%, and 22% in the nivolumab plus ipilimumab, nivolumab, and chemotherapy groups, respectively; PFS was 18%, 12%, and 4%. Patients with complete or partial response at 6 months had longer OS with nivolumab plus ipilimumab compared with chemotherapy.
Nivolumab plus ipilimumab provided long-term OS benefit in patients with NSCLC, and patients with PD-L1 ≥1% who achieved complete or partial response at 6 months had higher OS benefit with nivolumab plus ipilimumab compared with chemo.

9506 NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. M Maemondo, T Fukuhara, H Saito, et al

Take-Home Message

In this study, patients with EGFR-mutant advanced non-squamous NSCLC, who had not previously been on chemotherapy were randomized to receive erlotinib with bevacizumab or erlotinib alone. Median OS was 50.7 months and 46.2 months in the bevacizumab and erlotinib groups, respectively. A similar proportion of patients in both groups initiated second-line treatment with osimertinib, and median time to disease progression on osimertinib was similar between groups. Median OS of patients on osimertinib in both groups was longer than OS seen in other second-line chemotherapy groups.
Combination therapy with bevacizumab and erlotinib for EGFR-mutant NSCLC showed similar OS, second-line treatment initiation, and PFS2 when compared with erlotinib monotherapy.

9509 Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. M Waldron-Lynch, S Le Mouhaer, N Nwana, et al

Take-Home Message

In this study, patients with MET-amplified NSCLC (with gene copy number of 10 or higher) who had previously received one to two lines of systemic therapy (cohort 1a) or who were treatment-naïve (cohort 5a) received capmatinib 400 mg twice daily. The overall response rate was 29% and 40%, median duration of response was 8.31 months and 7.54 months, and median PFS was 4.07 months and 4.17 months in cohorts 1a and 5a, respectively. The most common adverse events seen in all cohorts were peripheral edema, nausea, and vomiting.
Capmatinib demonstrated clinical benefit in patients with a high level of MET-amplified NSCLC, and a higher response rate was seen in treatment-naïve patients.

9513 ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. Z Piotrowska, Y Wang, LV Sequist, et al

Take-Home Message

In this study, patients with advanced NSCLC with exon 20 insertion mutations in EGFR, who had at least one prior therapy, were treated with 160 mg of osimertinib daily. In the 20 patients who were evaluated, the objective response rate was 25% and stable disease was 60%. The median PFS was 9.7 months and median duration of response was 5.7 months. Grade 3 adverse events included anemia, fatigue, and a prolonged QT interval.
Osimertinib was well-tolerated and demonstrated clinical activity in patients with advanced NSCLC with exon 20 insertion mutations in EGFR.

ASCO 2020, longkanker, aanbevolen abstracten